Upload
tessy-lopez
View
216
Download
0
Embed Size (px)
Citation preview
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 1/22
Cancer: Catalytic
Tessy LópezUniversidad Autónoma Metropolitana
National Institute of Neurology andNeurosurgery
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 2/22
What is cancer?
Is a term used for diseases in which abnormal cells dividewithout control and are able to invade other tissues. Cancer cells can spread to other parts of the body through the blood
and lymphatic systems (metastasize).
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 3/22
ClassificaThis classification describes
the type of tissue in which thecancer cells begin to develop.
•
Adenocarcinoma - originates intissue
• Glioma – glial tissue
• Carcinoma– epithelial tissue
• Leukemia– blood cells
• Lymphoma– lymphatic tissue
• Myeloma– bone marrow
• –
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 4/22
Most cancers are named for
the organ or type of cell inwhich they begin.
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 5/22
Glioblastoma Multiforme(GBM) are 35% brain cancer,
according to the OMSstatistics. Those are theprimary and more frequenttumors of the Central
Nervous System (CNS).
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 6/22
NANOMEDICINE AND
Nanotechnology hasbeen applied in all
therapeutic areas of medicine.
The most extensiveinvestigations are in
cancer.
Nanoparticles can
deliver chemotherapydrugs directly to tumorcells and then give off asignal after the cells are
destroyed. Drugs
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 7/22
•
The treatment of Central NervousSystem (CNS) is difficult due to theBlood Brain Barrier (BBB) cross.
•
Only low molecular weightmolecules, liposolubles, and anypeptidic compounds cross the BBB.
Passive diffusion or specific
MECHANISM
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 8/22
Local application or direct tumor injection of cytotoxic drugs has been proposed as a
technique to use 100% .
Systemic exposure and non-target organ
toxicity is minimized
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 9/22
Gliadel: Drug delivery systemof carmustine in CNS to GBM
PRODUCT IN THE MARQUET
Only release thechemotherapy
during 10 days.
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 10/22
We have an alternative drug deliveryWe have an alternative drug delivery
System. This deliver during six monthsSystem. This deliver during six months
thetheFollowing drugs: Carmustine andFollowing drugs: Carmustine andRelease from TiO2 Release from SiO2
Tumor with C6
cancer cells Sol-gel device with drug
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 11/22
Catalytic Nanomedicineis a new wa to treat
We made a catalytic processin the nucleotides of the
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 12/22
BIO-CATALYST UAM-INNN
1. Cis Pt/SBA-15
2. Pt(acac)2/SiO2
3. Pt(acac)2/TiO2
4. H2PtCl6/SiO2
5. H2PtCl
6/TiO
26. Temozolomida/TiO2
7. (NH2)4Cl2Pt/ SiO2
8. Doxorubicina/SiO2
9. Metotrexato/SiO2
10.Cis-diamindicloro-Platino (II)B
11.Cis-diamindicloro-Platino (II)A
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 13/22
CHARACTERIZ
Pt/SiO2
640m2/g
Particle size of theSupport = 30 nmParticle size of thePlatinum = 3-5 nm
Brönsted andLewis acid sites
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 14/22
Pt/TiOC6 cellular model wasused to form
a tumor of 5 cm of diameter.
n = 70
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 15/22
Control Platinum complex
Titania Titania-Platinum
Control Platinum complex
Titania Titania-Platinum
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 16/22
0
10
20
30
40
50
60
CONTROL Pt TiO2 TiO2-Pt
T u m o r a l w e i g
t h ( g r )
*
*p=0.03 when compared with control
Tumoral weight reduction
24.6%
43.4%55.7%
Average tumor size of C6 glioma in rats after treatment
0
10
20
30
40
50
60
CONTROL Pt TiO2 TiO2-Pt
T u m o r a l w e i g
t h ( g r )
*
*p=0.03 when compared with control
Tumoral weight reduction
24.6%
43.4%55.7%
Average tumor size of C6 glioma in rats after treatment
96%
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 17/22
Particl
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 18/22
• A significant growth inhibitionwas observed in animal treated
with Platinum-titania .• The existence of stronger
electron-acceptor centers (Ti4+
and Ti3+
ions) that can coordinatewith basic molecules placed atDNA and promoted the apoptosismechanism.
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 19/22
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 20/22
t=0 t= 3 t=5 t=10
Degradation of DNA studies withour different
Nanoparticles: control release
7
t=72
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 21/22
8/14/2019 Nanotechnology 2008
http://slidepdf.com/reader/full/nanotechnology-2008 22/22Thank you